표적 알파 치료의 현황 및 유용성에 대한 임상적 고찰

키워드

참고문헌 (77)

1. Das T, "Options to meet the future global demand of radionuclides for radionuclide therapy", Nucl. Med. Biol, 40(1), pp.23~32 (2013)[DOI]
2. Yordanova A, "Theranostics in nuclear medicine practice", Onco Targets Ther, 10, pp.4821~4828 (2017)[DOI]
3. Moumaris M, "Nanomedical devices and cancer theranostics", Open Nanomedicine J, 6(1), pp.1~11 (2020)[DOI]
5. Majkowska-Pilip A, "Nanoparticles in targeted alpha therapy", Nanomaterials(Basel), 10(7), pp.1~25 (2020)[DOI]
6. Nedrow JR, "Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model", EJNMMI Res, 7(1), pp.57~ (2017)[DOI]
7. Ackerman NL, "The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides", Phys Med Biol, 57(3), pp.771~783 (2012)[DOI]
8. Seidlin SM, "Radioactive iodine therapy : Effect on functioning metastases of adenocarcinoma of the thyroid", J Am Med Assoc, 132(14), pp.838~847 (1946)[DOI]
9. Gudkov SV, "Targeted radionuclide therapy of human tumors", Int J Mol Sci, 17(1), pp.1~19 (2015)[DOI]
11. Cherel M, "Current status and perspectives in alpha radioimmunotherapy", Q. J. Nucl. Med. Mol. Imaging, 50, pp.322~329 (2006)[DOI]
12. Sgorous G, "Alpha-particles for targeted therapy", Adv Drug Deliv Rev, 60(12), pp.1402~1406 (2008)[DOI]
13. Harrison MR, "Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease", Cancer Manag. Res, 5, pp.1~14 (2013)[DOI]
14. Walicka MA, "Survival and DNA damage in chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211", Radiat. Res, 150(3), pp.263~268 (1998)[DOI]
15. Sgouros G, "Cancer stem cell targeting using the alpha-particle emitter, 213 Bi: Mathematical modeling and feasibility analysis George", Cancer Biother. Radiopharm, 23(1), pp.74~81 (2008)[DOI]
16. Poty S, "α-Emitters for radiotherapy: From basic radiochemistry to clinical studies-Part 2", J. Nucl. Med, 59(7), pp.1020~1027 (2018)[DOI]
17. Sollini M, "The five “W”s and “How” of targeted alpha therapy: Why? Who? What? Where? When? and How?", Rend. Fis. Acc. Lincei, 31, pp.231~247 (2020)[DOI]
18. Huang CY, "Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy", Med. Phys, 39(3), pp.1282~1288 (2012)[DOI]
19. Kassis AI, "Therapeutic radionuclides: Biophysical and radiobiologic principles", Semin. Nucl. Med, 38(5), pp.358~366 (2008)[DOI]
20. Tasnim I, "Range of alpha particles in human tissue", J of Engineering and Applied Science, 14(15), pp.5060~5063 (2019)[DOI]
21. Pouget JP, "General aspects of the cellular response to low- and high-LET radiation", Eur. J. Nucl. Med, 28(4), pp.541~561 (2001)[DOI]
22. Song H, "Alpha particle emitter radiolabeled antibody for metastatic cancer : What can we learn from heavy ion beam radiobiology?", Antibodies, 1(2), pp.124~148 (2012)[DOI]
23. Elbakry A, "Homologous recombination subpathways: A tangle to resolve. Sec. Human and Medical Genomics", Mini Review, 12, pp.1~7 (2021)[DOI]
24. Li X, "Homologous recombination in DNA repair and DNA damage tolerance", Cell Research, 18(1), pp.99~113 (2008)[DOI]
25. Hamada N, "Signaling pathways underpinning the manifestations of ionizing radiation-induced bystander effects", Curr Mol Pharmacol, 4(2), pp.79~95 (2011)[DOI]
26. Azzam EI, "Oxidative metabolism, gap junctions and the ionizing radiation-induced bystander effect", Oncogene, 22(45), pp.7050~7057 (2003)[DOI]
27. Azzam EI, "Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low uences of alpha particles", Radiat Res, 150, pp.497~504 (1998)[DOI]
28. Wu LJ, "Targeted cytoplasmic irradiation with alpha particles induces mutations in mammalian cells", Proc Natl Acad Sci USA, 96(9), pp.4959~4964 (1999)[DOI]
29. Azzam EI, "Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particleꠓirradiated normal human fibroblast cultures", Cancer Res, 62(19), pp.5436~5442 (2002)[DOI]
30. Matsumoto H, "Induction of radioresistance by a nitric oxide-mediated bystander effect", Radiat Res, 155(3), pp.387~396 (2001)
31. 2.0.co;2,
32. Sgouros G, "Radiopharmaceutical therapy in cancer : Clinical advances and challenges", Nat Rev Drug Discov, 19, pp.589~608 (2020)[DOI]
33. Strosberg J, "Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors", N Engl J Med, 376(2), pp.125~135 (2017)[DOI]
34. Pallares RM, "Transforming lanthanide and actinide chemistry with nanoparticles", Nanoscale, 12, pp.1339~1348 (2020)[DOI]
35. Yue J, "Smaller CpG-conjugated gold nanoconstructs achieve higher targeting specificity of immune activation", ACS Appl Mater Interfaces, 10(26), pp.21920~21926 (2018)[DOI]
36. Pallares RM, "Manipulating immune activation of macrophages by tuning the oligonucleotide composition of gold nanoparticles", Bioconjug Chem, 30(7), pp.2032~2037 (2019)[DOI]
37. Xie D, "A simplified model to calculate the surface-to-volume atomic ratio dependent cohesive energy of nanocrystals", J Phys Condensed Matter, 16(36), pp.401~405 (2004)[DOI]
38. Piotrowska A, "Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy", Nucl Med Biol, 47, pp.10~18 (2017)[DOI]
39. Sattiraju A, "Alpha particle enhanced blood brain", tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3-targeted liposomes, 2017, pp.16(10), 2191~2200
40. Mckeage K, "Trastuzumab : A review of its use in the treatment of metastatic breast cancer overexpressing HER2", Drugs, 62(1), pp.209~243 (2002)[DOI]
41. Caron PC, "A phase 1B trial of humanized monoclonal antibody M195(anti-CD33)in myeloid leukemia : Specific targeting without immunogenicity", Blood, 83(7), pp.1760~1768 (1994)[DOI]
42. Simmons D, "Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells", J Immunol, 141(8), pp.2797~2800 (1988)[DOI]
43. Chang SS, "Overview of prostate-specific membrane antigen", Rev Urol, 6, pp.S13~S18 (2004)[DOI]
44. Kratochwil C, "225Ac-PSMA-617for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer", J Nucl Med, 57(12), pp.1941~1944 (2016)[DOI]
45. Sathekge M, "225Ac-PSMA-617in chemotherapy-naive patients with advanced prostate cancer : A pilot study", Eur J Nucl Med Mol Imaging, 46(1), pp.129~138 (2019)[DOI]
46. Couturier O, "Cancer radioimmunotherapy with alpha-emitting nuclides", Eur J Nucl Med Mol Imaging, 32(5), pp.601~614 (2005)[DOI]
47. Scheinberg DA, "Actinium-225 in targeted alpha-particle therapeutic applications", Curr Radiopharm, 4(4), pp.306~320 (2011)[DOI]
48. Wadas TJ, "Molecular targeted α-particle therapy for oncologic applications", Am J Roentgenol, 203(2), pp.253~260 (2014)[DOI]
49. McDevitt MR, "Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use", J Nucl Med, 40(10), pp.1722~1727 (1999)[DOI]
50. Larsen RH, "Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211 at reaction", Appl. Radiat. Isot, 47(2), pp.135~143 (1996)[DOI]
51. Nilsson S, "First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases", Clin. Cancer Res, 11(12), pp.4451~4459 (2005)[DOI]
52. Larsen RH, "Preparation of 227Th-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability", Cancer Biother. Radiopharm, 22, pp.431~437 (2007)[DOI]
53. Kozak RW, "Bismuth-212-labeled anti-tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy", Proc. Natl. Acad. Sci. USA, 83(2), pp.474~478 (1986)[DOI]
54. Parker C, "Overall survival benefit of Radium223 Chloride (Alpharadin™)in the treatment of patients with symptomatic bone metastases in Castration-resistant Prostate Cancer (CRPC): A phase III randomized trial (ALSYMPCA)", European Journal of Cancer, 47(2), pp.3~3 (2011)[DOI]
55. Tagawa ST, "Phase I study of 225Ac-J591for men with metastatic castration-resistant prostate cancer (mCRPC)", J. Clin. Oncol, 39(15), pp.5015~ (2021)[DOI]
56. Tagawa ST, "Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT)with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T", J. Clin. Oncol, 41, pp.5018~ (2023)[DOI]
57. Jurcic GJ, "Targeted αparticle immunotherapy for myeloid leukemia", Blood, 100(4), pp.1233~1239 (2002)[DOI]
58. Rosenblat TL, "Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab(HuM195)for acute myeloid leukemia", Clin Cancer Res, 16(21), pp.5303~5311 (2010)[DOI]
60. Schmidt DF, "Phase 1 clinical study on alpha-therapy for non-Hodgkin lymphoma", 4th Alpha-Immunotherapy Symposium (2004)
61. octreotate: Toxicity, efficacy, and survival, "J. Clin. Oncol", 2008, 2124~2130, https:
62. Kratochwil C, "213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience", Eur. J. Nucl. Med. Mol. Imaging, 41(11), pp.2106~2119 (2014)[DOI]
64. Krolicki L, "Safety and efficacy of targeted alpha therapy with 213Bi-DOTAsubstance P in recurrent glioblastoma", Eur J Nucl Med Mol Imaging, 46(3), pp.614~622 (2019)[DOI]
65. -substance P : A pilot trial, "Eur J Nucl Med Mol Imaging", 2010, 1335~1344, https:
66. Zalutsky MR, "Clinical experience with alpha-particle emitting 211At : Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6", J Nucl Med, 49(1), pp.30~38 (2008)[DOI]
67. Andersson H, "Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2-A phase I study", J. Nucl. Med, 50(7), pp.1153~1160 (2009)[DOI]
68. Pallares RM, "Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?", Front. Med, pp.1~16 (2022)[DOI]
69. Allen BJ, "Targeted alpha therapy for cancer", Phys Med Biol, 49(16), pp.3703~3712 (2004)[DOI]
70. McDevitt MR, "Radioimmunotherapy with alpha-emitting nuclides", Eur J Nucl Med, 25(9), pp.1341~1351 (1998)[DOI]
71. Cordes N, "Cell adhesion-mediated radioresistance(CAM-RR) : Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro", Strahlenther Onkol, 179(5), pp.337~344 (2003)[DOI]
72. Radchenko V, "Production and supply of alpha particles emitting radionuclides for Targeted Alpha Therapy(TAT)", J Nucl Med, 62(11), pp.1495~1503 (2021)[DOI]
73. Pouget JP, "Revisiting the radiobiology of targeted alpha therapy", Front Med, 8, pp.1~11 (2021)[DOI]
74. Kim YS, "An overview of targeted alpha therapy", Tumor Biol, 33(3), pp.573~590 (2012)[DOI]
75. Morgenstern A, "An overview of targeted alpha therapy with actinium-225 and bismuth-213", Curr Radiopharm, 11(3), pp.200~208 (2018)[DOI]
76. 최상규, "첨단 암 치료로서 중입자치료의 임상적 유용성에 대한 고찰", 방사선기술과학, 42(6), pp.413~422 (2019), 대한방사선과학회
77. 송관수, "전립선암에 대한 토모치료와 양성자치료의 치료계획 비교", 방사선기술과학, 36(1), pp.31~38 (2013), 대한방사선과학회

관련 논문AI추천